Taken together, these results suggest that the hepatic knockout of Zbtb7b leads to lipid accumulation in the liver and triggers inflammation during HFD‐induced MASLD progression. Here, ZBTB7B is linked to metabolic dysfunction-associated steatotic liver disease.